478 related articles for article (PubMed ID: 29525076)
1. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.
Kasner SE; Lavados P; Sharma M; Wang Y; Wang Y; Dávalos A; Shamalov N; Cunha L; Lindgren A; Mikulik R; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi R; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni DS; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; DeVries Basson MM; Endres M; Muir K; Bornstein N; Ozturk S; O'Donnell M; Mundl H; Pater C; Weitz J; Peacock WF; Swaminathan B; Kirsch B; Berkowitz SD; Peters G; Pare G; Themeles E; Shoamanesh A; Connolly SJ; Hart RG;
J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1673-1682. PubMed ID: 29525076
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Hart RG; Veltkamp RC; Sheridan P; Sharma M; Kasner SE; Bangdiwala SI; Ntaios G; Shoamanesh A; Ameriso SF; Toni D; Czlonkowska A; Lindgren A; Hankey GJ; Perera KS; Shuaib A; Coutts SB; Gagliardi RJ; Berkowitz SD; Mundl H; Peters G; Connolly SJ;
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2273-2279. PubMed ID: 31160218
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Sharma M; Smith EE; Pearce LA; Shoamanesh A; Perera KS; Coutts SB; Damgaard D; Ameriso SF; Rha JH; Modrau B; Yoon BW; Romano M; Messé SR; Barlinn J; Lambeck J; Saad F; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
Stroke; 2022 Jan; 53(1):45-52. PubMed ID: 34538089
[TBL] [Abstract][Full Text] [Related]
4. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Merkler AE; Pearce LA; Kasner SE; Shoamanesh A; Birnbaum LA; Kamel H; Sheth KN; Sharma R
JAMA Neurol; 2021 Dec; 78(12):1454-1460. PubMed ID: 34694346
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
Veltkamp R; Pearce LA; Korompoki E; Sharma M; Kasner SE; Toni D; Ameriso SF; Mundl H; Tatlisumak T; Hankey GJ; Lindgren A; Berkowitz SD; Arauz A; Ozturk S; Muir KW; Chamorro Á; Perera K; Shuaib A; Rudilosso S; Shoamanesh A; Connolly SJ; Hart RG
JAMA Neurol; 2020 Oct; 77(10):1233-1240. PubMed ID: 32628266
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy.
Sharma M; Smith EE; Pearce LA; Perera KS; Kasner SE; Yoon BW; Ameriso SF; Puig J; Damgaard D; Fiebach JB; Muir KW; Veltkamp RC; Toni DS; Shamalov N; Gagliardi RJ; Mikulik R; Engelter ST; Bereczki D; O'Donnell MJ; Saad F; Shoamanesh A; Berkowitz SD; Mundl H; Hart RG;
Int J Stroke; 2022 Aug; 17(7):799-805. PubMed ID: 34791941
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
[TBL] [Abstract][Full Text] [Related]
8. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Ntaios G; Pearce LA; Veltkamp R; Sharma M; Kasner SE; Korompoki E; Milionis H; Mundl H; Berkowitz SD; Connolly SJ; Hart RG;
Stroke; 2020 Jun; 51(6):1797-1804. PubMed ID: 32295509
[TBL] [Abstract][Full Text] [Related]
9. Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS.
Uchiyama S; Toyoda K; Kitagawa K; Okada Y; Ameriso S; Mundl H; Berkowitz S; Yamada T; Liu YY; Hart RG;
Int J Stroke; 2019 Dec; 14(9):915-922. PubMed ID: 31132967
[TBL] [Abstract][Full Text] [Related]
10. Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
Ameriso SF; Amarenco P; Pearce LA; Perera KS; Ntaios G; Lang W; Bereczki D; Uchiyama S; Kasner SE; Yoon BW; Lavados P; Firstenfeld A; Mikulik R; Povedano GP; Ferrari J; Mundl H; Berkowitz SD; Connolly SJ; Hart RG
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104936. PubMed ID: 32689594
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Ntaios G; Swaminathan B; Berkowitz SD; Gagliardi RJ; Lang W; Siegler JE; Lavados P; Mundl H; Bornstein N; Meseguer E; Amarenco P; Cucchiara B; Camps-Renom P; Makaritsis K; Korompoki E; Papavasileiou V; Marti-Fabregas J; Milionis H; Vemmos K; Connolly SJ; Hart RG;
Stroke; 2019 Sep; 50(9):2477-2485. PubMed ID: 31401971
[TBL] [Abstract][Full Text] [Related]
12. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Shoamanesh A; Hart RG; Connolly SJ; Kasner SE; Smith EE; Martí-Fàbregas J; Liu YY; Uchiyama S; Mikulik R; Veltkamp R; O'Donnell MJ; Ntaios G; Muir KW; Field TS; Santo GC; Olavarria V; Mundl H; Lutsep H; Berkowitz SD; Sharma M
JAMA Neurol; 2021 Jan; 78(1):11-20. PubMed ID: 33074284
[TBL] [Abstract][Full Text] [Related]
13. High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source.
Scheitz JF; Pare G; Pearce LA; Mundl H; Peacock WF; Czlonkowska A; Sharma M; Nolte CH; Shoamanesh A; Berkowitz SD; Krahn T; Endres M;
Stroke; 2020 Aug; 51(8):2386-2394. PubMed ID: 32640945
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Healey JS; Gladstone DJ; Swaminathan B; Eckstein J; Mundl H; Epstein AE; Haeusler KG; Mikulik R; Kasner SE; Toni D; Arauz A; Ntaios G; Hankey GJ; Perera K; Pagola J; Shuaib A; Lutsep H; Yang X; Uchiyama S; Endres M; Coutts SB; Karlinski M; Czlonkowska A; Molina CA; Santo G; Berkowitz SD; Hart RG; Connolly SJ
JAMA Neurol; 2019 Jul; 76(7):764-773. PubMed ID: 30958508
[TBL] [Abstract][Full Text] [Related]
15. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Diener HC; Easton JD; Granger CB; Cronin L; Duffy C; Cotton D; Brueckmann M; Sacco RL;
Int J Stroke; 2015 Dec; 10(8):1309-12. PubMed ID: 26420134
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Hill MD; Jonasson J; Kasner SE; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
Stroke; 2017 Sep; 48(9):2480-2487. PubMed ID: 28720658
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Hart RG; Sharma M; Mundl H; Kasner SE; Bangdiwala SI; Berkowitz SD; Swaminathan B; Lavados P; Wang Y; Wang Y; Davalos A; Shamalov N; Mikulik R; Cunha L; Lindgren A; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi RJ; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni D; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; Endres M; Muir KW; Bornstein N; Ozturk S; O'Donnell MJ; De Vries Basson MM; Pare G; Pater C; Kirsch B; Sheridan P; Peters G; Weitz JI; Peacock WF; Shoamanesh A; Benavente OR; Joyner C; Themeles E; Connolly SJ;
N Engl J Med; 2018 Jun; 378(23):2191-2201. PubMed ID: 29766772
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Hart RG; Sharma M; Mundl H; Shoamanesh A; Kasner SE; Berkowitz SD; Pare G; Kirsch B; Pogue J; Pater C; Peters G; Davalos A; Lang W; Wang Y; Wang Y; Cunha L; Eckstein J; Tatlisumak T; Shamalov N; Mikulik R; Lavados P; Hankey GJ; Czlonkowska A; Toni D; Ameriso SF; Gagliardi RJ; Amarenco P; Bereczki D; Uchiyama S; Lindgren A; Endres M; Brouns R; Yoon BW; Ntaios G; Veltkamp R; Muir KW; Ozturk S; Arauz A; Bornstein N; Bryer A; O'Donnell MJ; Weitz J; Peacock F; Themeles E; Connolly SJ
Eur Stroke J; 2016 Sep; 1(3):146-154. PubMed ID: 31008276
[TBL] [Abstract][Full Text] [Related]
19. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Ntaios G; Pearce LA; Meseguer E; Endres M; Amarenco P; Ozturk S; Lang W; Bornstein NM; Molina CA; Pagola J; Mundl H; Berkowitz SD; Liu YY; Sen S; Connolly SJ; Hart RG
Stroke; 2019 Nov; 50(11):3184-3190. PubMed ID: 31526123
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial.
Bosch J; Pearce LA; Sharma M; Canavan M; Whiteley WN; Mikulík R; Mundl H; Yusuf S; Hart RG; O'Donnell MJ
J Stroke Cerebrovasc Dis; 2022 May; 31(5):106404. PubMed ID: 35292423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
